

**2017 No. 632**

**DANGEROUS DRUGS, ENGLAND AND WALES**

**DANGEROUS DRUGS, SCOTLAND**

**The Misuse of Drugs (Designation) (Amendment) (England,  
Wales and Scotland) Order 2017**

*Made* - - - - *6th May 2017*

*Coming into force* *31st May 2017*

*To be laid before Parliament*

The Secretary of State, in exercise of the powers conferred by sections 7(4) and 7(5) of the Misuse of Drugs Act 1971(a), and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act, makes the following Order:

**Citation, commencement and extent**

**1.**—(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 and comes into force on 31st May 2017.

(2) This Order extends to England and Wales and Scotland.

**Amendment to the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015**

**2.**—(1) The Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015(b) is amended as follows.

(2) In paragraph 1(a) of Part 1 of the Schedule—

(a) before “Bufotenine” insert—

“Adinazolam (1-(8-Chloro-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-1-yl)-*N,N*-dimethylmethanamine)

*N*-Benzyl-ethylphenidate

Bromazolam (8-bromo-1-methyl-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine)”;

(b) after “Cathinone” insert—

“4'-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)

---

(a) 1971 c. 38.

(b) S.I. 2015/704 as amended by S.I. 2016/1124.

- Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4*H*-[1,2,4]triazolo[4,3-*a*][1,4] benzodiazepine”);
- (c) after “Concentrate of poppy-straw” insert—
- “Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4] diazepine)
- 3,4-Dichloroethylphenidate
- 3,4-Dichloromethylphenidate (3,4-DCMP)
- Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)
- Ethyl-naphthidate
- Ethylphenidate”;
- (d) after “Eticyclidine” insert—
- “Etizolam”;
- (e) after “Etryptamine” insert—
- “Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)
- Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4] benzodiazepine)
- 4-Fluoroethylphenidate
- 4-Fluoromethylphenidate
- Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one”);
- (f) after “Gamma-butyrolactone” insert—
- “3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)
- Isopropylphenidate (IPP or IPPD)”;
- (g) after “Lysergide and other *N*-alkyl derivatives of lysergamide” insert—
- “Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one”);
- (h) after “Methcathinone” insert—
- “4-Methylmethylphenidate
- Methylmorphenate
- Methylnaphthidate (HDMP-28)
- Metizolam (4-(2-Chlorophenyl)-2-ethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4] diazepine)
- Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one)
- Nitrazolam (1-Methyl-8-nitro-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine)
- Propylphenidate”;
- (i) after “Psilocin” insert—
- “Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4] benzodiazepine”);

(j) after “3,4-dichloro-*N*-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)”  
insert—

“3,4-dichloro-*N*-[2-(dimethylamino)cyclohexyl]-*N*-methylbenzamide (U-47,700)”.

Home Office  
6th May 2017

*Sarah Newton*  
Parliamentary Under Secretary of State

### **EXPLANATORY NOTE**

*(This note is not part of the Order)*

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (S.I. 2015/704) by inserting a synthetic opioid (U-47,700), several methylphenidate related materials and a number of designer benzodiazepines into Part 1 of the Schedule to that Order.

An impact assessment will be published alongside the Explanatory Memorandum on the [legislation.gov.uk](http://legislation.gov.uk) website.

---

© Crown copyright 2017

Printed and published in the UK by The Stationery Office Limited under the authority and superintendence of Carol Tullo, Controller of Her Majesty's Stationery Office and Queen's Printer of Acts of Parliament.

£4.25

UK201705096 05/2017 19585

<http://www.legislation.gov.uk/id/uksi/2017/632>

ISBN 978-0-11-115836-4



9 780111 158364